Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22409410 | 1.00 | MEN1 (0.41) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL22409448 | 0.90 | MEN1 (0.41) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL22409446 | 0.90 | MEN1 (0.41) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL19014628 | 0.82 | NPC1 (0.40) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL19475727 | 0.82 | MEN1 (0.43) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL19475726 | 0.82 | MEN1 (0.43) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL1540211 | 0.81 | MAOA (0.47) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL19145150 | 0.81 | MAOA (0.47) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL1541038 | 0.81 | LTA4H (0.47) | MEN1KMT2AALDH1A1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL31570866 | 0.80 | MAOA (0.45) | MEN1KMT2ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | UNITY BIOTECHNOLOGY, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | ACAT1, ARSA, GLA | MEN1 2555/4885KMT2A 1493/4885NPC1 667/4885 |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | ACAT1, ARSA, GLA | MEN1 2555/4885KMT2A 1493/4885NPC1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.